Brittany Sexton, PhD | American Lung Association

Brittany Sexton, PhD

Research Awards Nationwide Recipient (2016-2017)

Massachusetts General Hospital
Funded by LUNG FORCE
Discovering Inner Workings of Enzyme Could Lead to Lung Cancer Treatment

Abnormal duplication of genes contributes to lung cancer risk and associated drug resistance. We will study the enzyme KDM4A, which is overexpressed (makes too many copies) in lung cancer, and leads to a higher frequency of copies of genetic regions linked to drug resistance and increased potential for the spread of lung cancer. KDM4A overexpression in cancer cells also results in reduced response to chemotherapy. We will determine the relationship between KDM4A expression levels, extra copies of drug resistant regions and their impact on drug resistance in lung cancer. These studies could lead to development of new treatments for lung cancer.

Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.